Combined phlebotomy and ursodeoxycholic acid treatment in the patients with chronic hepatitis C

Hepatology Research

Volumn 18, Issue 1, 2000, Pages 54-62

  Wakusawa, Shinya ^a   Ikeda, Ritsuko ^a   Takikawa, Toshikuni ^a   Hayashi, Hisao ^a   Yano, Motoyoshi ^b   Yoshioka, Kentaro ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b NONE

Author keywords

Aminotransferases; Bile acid; Interferon; Iron; RNA

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; GAMMA GLUTAMYLTRANSFERASE; INTERFERON; IRON; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; MALE; MONOTHERAPY; PHLEBOTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 0034026293     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(99)00084-4     Document Type: Article

References (27)

1. Hoofnagle A.H. Hepatitis C: the clinical spectrum of diseases. Hepatology. 26:1997;15S-20S.
2. Bonkovsky H.L. Therapy of hepatitis C: other options. Hepatology. 26:1997;1435-1515.
3. Van Thiel DH, DiBisceglie, Piperno A. γ-Glutamyl transpeptidase as a response prediction when using a-interferon to treat hepatitis C. Hepato-Gastroenterology 1995;42:888-892.
4. Bonkovsky H.L. Iron and chronic viral hepatitis. Hepatology. 25:1997;759-768.
5. Isomura T., Yano M., Hayashi H., Sakamoto N. Excess iron in the liver of patients with chronic hepatitis C. J. Clin. Electron. Microsc. 25:1992;231-237.
6. Hayashi H., Takikawa T., Nishimura N., Yano M., Isomura T., Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am. J. Gastroenterol. 89:1994;986-988.
7. Hayashi H., Takikawa T., Nishimura N., Yano M. Serum amonotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J. Hepatol. 22:1995;268-271.
8. Hayashi H., Wakusawa S., Takikawa T., Ikeda R., Yano M., Yoshioka K. Long-term effect of iron removal on chronic hepatitis C. Hepatology. 26:1997;215A.
9. Takano S., Ito Y., Yokosuka O., Uchiumi K., Hirota K., Omata M. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology. 20:1994;558-564.
10. Higuchi T., Hishida N., Isomura T., Takeshima H., Hayashi H. The effectual level of ursodeoxycholic acid in therapy for non-advanced chronic cholestasis is 50% of total serum bile acids. Gastroenterol. Jpn. 27:1992;222-229.
11. Okuyama S, Kokubun N, Higashidate S, Umemura D, Hirata Y. A new analytical method of individual bile acids by high performance liquid chromatography and immobilized 3-hydroxysteroid dehydrogenese in colum form, Chem. Lett. 1979;1443-1446.
12. Britton R. Metal-induced hepatotoxicity. Semin. Liver. Dis. 16:1996;3-12.
13. Kato J., Kobune M., Kohgo Y., Sugawara N., Hisai H., Nakamura T. et al. Hepatic iron deprivation prevents spontaneous development of fulminant hepatitis and liver cancer in Long-Evans Cinnamon rats. J. Clin. Invest. 98:1996;923-929.
14. Ikeda R., Ohtani K., Hattori K., Shiono Y., Arai N., Takikawa T. et al. Iron removal for prophylaxis of Long-Evans Cinnamon (LEC) rat fulminant hepatitis. Hepatology. 24:1996;526A.
15. Tsukamoto H., Horne W., Kamimura S., Niemela O., Parkkila S., Yla-Herttuala S. et al. Experimental liver cirrhosis induced by alcohol and iron. J. Clin. Invest. 96:1995;620-630.
16. Olynyk J., Hall P., Reed W., Williams P., Kerr R., Mackinnon M. A long-term study of the interaction between iron and alcohol in an animal model of iron overload. J. Hepatol. 22:1995;671-676.
17. Stal P., Johansson I., Ingelman-Sundberg M., Hagen K., Hultcrantz R. Hepatotoxicity induced by iron overload and alcohol. Studies on the role of chelatable iron, cytochrome P450 2E1 and lipid peroxidation. J. Hepatol. 25:1996;538-546.
18. Yano M., Yoshioka K., Takikawa T., Hayashi H. Long term phlebotomy suppresses the progression of liver histological staging in patients with chronic hepaitis C. Hepatology. 28:1998;474A.
19. Leuschner U., Leuschner M., Sieratzki J., Kurtz W., Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up: a pilot study. Dig. Dis. Sci. 30:1985;642-649.
20. Takikawa H., Yamanaka M., Miyake K., Kako M., Ohki H., Narita T. et al. Ursodeoxycholic acid therapy for chronic type C hepatitis: a multicenter, dose-finding trial. Curr. Ther. Res. 55:1994;16-21.
21. Crosignani A., Battezzati P.M., Stechell K.D.R., Camisasca M., Bertolini E., Roda A. et al. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study. Hepatology. 13:1990;339-344.
22. Hofmann A.F., Popper H. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet. 2:1987;398-399.
23. Rodrigues C.M.P., Guangsheng F., Ma X., Kren B.T., Steer C.J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J. Clin. Invest. 101:1998;2790-2799.
24. Piperno A., Sampietro M., D'Alba R., Roffi L., Fargion S., Parma S. et al. Iron store, response to a-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver. 16:1996;248-254.
25. Kakumu S., Yoshioka K., Tanaka K., Higashi Y., Kurokawa S., Hirofuji H. et al. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chroNic hepatitis C. J. Med. Virol. 41:1993;65-70.
26. Kasahara A., Hayashi N., Mochizuki K., Takayanagi M., Yoshioka K., Kakumu S. et al. Risk factors for hepatocellular arcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 27:1998;1394-1402.
27. Lurie Y., Beer-Gabel M., Malnick S.D.H., Lambort I., Soumatzki T., Kaftory A. et al. Phlebotomy lowers serum ALT and alpha-fetoprotein levels in patients with chronic haptitis C. Hepatology. 26:1997;215A.